JSR Life Sciences to Establish Corporate Venture Fund for the Acceleration of Novel Therapies and Technologies
The fund will focus on emerging life science companies with novel platforms and methods to improve therapeutic outcomes and those with technologies that support science research, development, and manufacturing.
JSR Life Sciences announced on March 23, 2021 that it has launched its “JSR Life Sciences Corporate Venture Fund” to identify and accelerate novel therapies and technologies by investing in several deals within the next few years.
According to a company press release, the fund, which will be facilitated by Jason Yuanxin Zhang, PhD, will focus on emerging life science companies with novel platforms and methods to improve therapeutic outcomes and those with technologies that support science research, development, and manufacturing.
“JSR Life Sciences has extensive global knowledge and experience with early stage research, discovery, and technology that improves clinical outcomes. We are uniquely positioned to understand what works and what the market needs,” said Jean-Pierre Wery, PhD, chief technology officer for JSR Life Sciences, in the press release. “Initiating this fund and offering the ability to invest in the life sciences sector is a natural extension of our core expertise. [Zhang’s] ability to connect with contacts in many different facets of our industry, along with his experience in forging relationships and identifying promising assets, make him optimally qualified to identify opportunities for long-term value in our industry.”
“I look forward to working with JSR Life Sciences as the Company enters a major inflection point with its new corporate venture fund,” added Zhang in the press release. “I value JSR’s dedication to discovering new therapies and technologies and look forward to bringing my experience in leadership, growth, and business development to support their work.”
Source: JSR
